What is Greater Cannabis's earnings per share (EPS)?

Greater Cannabis (GCAN) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Greater Cannabis Financials

GCAN

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Greater Cannabis (GCAN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GCAN FY2025 2026-05-13

The dominant mechanic is balance-sheet depletion: liabilities persist while cash and near-term resources are being exhausted.

Between FY2023 and FY2025, cash fell from $167K to $815 while total liabilities stayed roughly flat; that matters more than the earlier narrowing losses because obligations were not being worked down as liquid resources vanished. The current ratio sliding from 0.2x to 0.001x shows the company moved from already tight liquidity to a position where even small claims would have little asset coverage.

From FY2022 to FY2024, net loss narrowed from -$360K to -$179K. But operating cash burn still sat near -$100K in each of the last two reported years, which implies the lower loss was not yet a self-funding operating model.

By FY2025, total assets were only $815 against total liabilities of $742K, so the balance sheet had almost no remaining cushion. Because current assets were essentially all cash in earlier years and then nearly disappeared, this looks less like an inventory or receivables squeeze and more like the simple exhaustion of liquid resources.

Financial Health Signals

Financial Profile 0/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Greater Cannabis's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Liquidity

Greater Cannabis's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$0.00

Greater Cannabis earned $0.00 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$815

YoY-98.6%

5Y CAGR-62.7%

Greater Cannabis held $815 in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

944,935

YoY+76.1%

Greater Cannabis had 944,935 shares outstanding in fiscal year 2025. This represents an increase of 76.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

GCAN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	$13K-73.7%	$48K
Cost of Revenue	N/A	N/A	N/A	N/A	$13K-73.7%	$48K
Gross Profit	N/A	N/A	N/A	N/A	-$25+45.7%	-$46
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	-$156K+10.9%	-$175K+0.9%	-$177K+48.4%	-$343K-16.5%	-$294K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$179K+5.0%	-$188K+47.7%	-$360K+40.2%	-$602K	N/A
EPS (Diluted)	$0.00	$0.00	$0.00	$0.00	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	-$37K+22.5%	-$48K-10.8%	-$44K	N/A	-$40K-3.0%	-$39K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	-$36K	N/A	-$104K	N/A	-$46K-2.8%	-$45K
EPS (Diluted)	$0.00	N/A	$-0.04	$0.00	$0.00	N/A	$-0.09	$0.00

GCAN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$815-98.6%	$58K-66.5%	$172K-38.6%	$280K-28.6%	$393K+118.2%	$180K
Current Assets	$815-98.6%	$57K-65.6%	$167K-38.2%	$270K-28.5%	$378K+136.4%	$160K
Cash & Equivalents	$815-98.6%	$57K-65.6%	$167K-38.2%	$270K-28.5%	$378K+234.2%	$113K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$742K-17.3%	$898K+7.7%	$834K+1.0%	$825K-4.3%	$862K+87.4%	$460K
Current Liabilities	$742K-17.3%	$898K+7.7%	$834K+1.0%	$825K-4.3%	$862K+87.4%	$460K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$742K+11.7%	-$840K-27.1%	-$661K-21.4%	-$545K-16.2%	-$469K-67.6%	-$280K
Retained Earnings	-$5.0M-7.1%	-$4.7M-4.0%	-$4.5M-4.4%	-$4.3M-9.2%	-$3.9M-18.1%	-$3.3M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$1K+76.6%	$815-96.2%	$21K-20.1%	$27K-42.2%	$46K-20.0%	$58K-9.6%	$64K-23.2%	$83K
Current Assets	$1K+76.6%	$815-96.2%	$21K-20.1%	$27K-42.2%	$46K-19.4%	$57K-7.9%	$62K-22.5%	$80K
Cash & Equivalents	$1K+76.6%	$815-96.2%	$21K-20.1%	$27K-42.2%	$46K-19.4%	$57K-7.9%	$62K-22.5%	$80K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$776K+4.6%	$742K-34.3%	$1.1M+2.8%	$1.1M+26.3%	$870K-3.1%	$898K+4.3%	$861K+3.2%	$834K
Current Liabilities	$776K+4.6%	$742K-34.3%	$1.1M+2.8%	$1.1M	N/A	$898K+4.3%	$861K+3.2%	$834K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$775K-4.5%	-$742K+33.1%	-$1.1M-3.4%	-$1.1M-30.1%	-$824K+1.9%	-$840K-5.4%	-$797K-6.1%	-$751K
Retained Earnings	-$5.0M-0.7%	-$5.0M+6.3%	-$5.3M-0.7%	-$5.3M-8.0%	-$4.9M-5.2%	-$4.7M-0.9%	-$4.6M-1.0%	-$4.6M

GCAN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	-$109K-6.1%	-$103K+4.0%	-$107K+54.3%	-$235K+18.7%	-$290K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	-$62K
Financing Cash Flow	$4K	N/A	N/A	N/A	$500K+13.7%	$440K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$4K	N/A	-$5K+72.5%	-$20K-74.8%	-$11K-127.0%	-$5K+72.8%	-$18K+63.2%	-$49K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$5K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GCAN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	-0.2%-0.1pp	-0.1%
Operating Margin	N/A	N/A	N/A	N/A	-2716.9%-2104.0pp	-612.9%
Net Margin	N/A	N/A	N/A	N/A	-4768.2%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-309.8%-200.5pp	-109.4%+19.1pp	-128.5%+24.8pp	-153.3%	N/A
Current Ratio	0.00-0.1	0.06-0.1	0.20-0.1	0.33-0.1	0.44+0.1	0.35
Debt-to-Equity	-1.00+0.1	-1.07+0.2	-1.26+0.3	-1.51+0.3	-1.84-0.2	-1.64
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	-169.0%	N/A	-224.0%	N/A	-72.2%-18.2pp	-54.0%
Current Ratio	0.000.0	0.00-0.0	0.020.0	0.02	N/A	0.060.0	0.07-0.0	0.10
Debt-to-Equity	-1.000.0	-1.00+0.0	-1.020.0	-1.02+0.0	-1.06+0.0	-1.07+0.0	-1.08+0.0	-1.11
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$742K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Livewire LVVV

$372K

CuraScientific copr CSTF

$377K

Transglobal Asse TMSH

$343K

Digicann Ventures Inc. AGFAF

$346K

Vibe Growth Corporation VIBEF

$281K

Frequently Asked Questions

What are Greater Cannabis's total assets?

Greater Cannabis (GCAN) had $815 in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Greater Cannabis have outstanding?

Greater Cannabis (GCAN) had 944,935 shares outstanding as of fiscal year 2025.

What is Greater Cannabis's current ratio?

Greater Cannabis (GCAN) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Greater Cannabis's debt-to-equity ratio?

Greater Cannabis (GCAN) had a debt-to-equity ratio of -1.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Greater Cannabis's debt-to-equity ratio negative or unusual?

Greater Cannabis (GCAN) has negative shareholder equity of -$742K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Greater Cannabis?

Greater Cannabis (GCAN) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.